2019
227 Mix methods approach to determine patients’ perspectives on the acceptability of a urinary biomarker test in replacement of cystoscopy for bladder cancer surveillance
Tan W, Teo C, Chan D, Heinrich M, Feber A, Sarpong R, Allan J, Williams N, Brew-Graves C, Ng C, Kelly J. 227 Mix methods approach to determine patients’ perspectives on the acceptability of a urinary biomarker test in replacement of cystoscopy for bladder cancer surveillance. European Urology Open Science 2019, 18: e303. DOI: 10.1016/s1569-9056(19)30219-2.Peer-Reviewed Original Research
2018
The role of circulating tumour cells and nucleic acids in blood for the detection of bladder cancer: A systematic review
Khetrapal P, Lee M, Tan W, Dong L, de Winter P, Feber A, Kelly J. The role of circulating tumour cells and nucleic acids in blood for the detection of bladder cancer: A systematic review. Cancer Treatment Reviews 2018, 66: 56-63. PMID: 29684744, DOI: 10.1016/j.ctrv.2018.03.007.Peer-Reviewed Original ResearchConceptsCirculating tumor cellsBladder cancerBlood-based biomarkersValidation cohortTumor cellsDiagnostic value of circulating tumor cellsCirculating tumor cell biomarkerDetection of bladder cancerSystematic reviewCell-free DNAIndependent validation cohortCirculating nucleic acidsSolid cancersAUC/ROC valueUrinary biomarkersMedian numberDiagnostic valueCancerBiomarker sensitivityBiomarkersNucleic acidsBladderSystematic searchCohortAUC/ROC
2016
Management of non-muscle invasive bladder cancer: A comprehensive analysis of guidelines from the United States, Europe and Asia
Tan W, Rodney S, Lamb B, Feneley M, Kelly J. Management of non-muscle invasive bladder cancer: A comprehensive analysis of guidelines from the United States, Europe and Asia. Cancer Treatment Reviews 2016, 47: 22-31. PMID: 27231966, DOI: 10.1016/j.ctrv.2016.05.002.Peer-Reviewed Original ResearchConceptsNon-muscle invasive bladder cancerBladder cancerAnalysis of guidelinesBladder cancer casesUnited StatesCancer casesInvasive bladder cancerIntravesical treatmentTransurethral resectionExpensive cancerTreatment modalitiesSurveillance protocolsContemporary guidelinesUnited KingdomGuidelinesIntensive treatmentBladderCancerInternational ConsultationTreatmentConsultationUnits
2014
Loss of expression of the tumour suppressor gene AIMP3 predicts survival following radiotherapy in muscle‐invasive bladder cancer
Gurung P, Veerakumarasivam A, Williamson M, Counsell N, Douglas J, Tan W, Feber A, Crabb S, Short S, Freeman A, Powles T, Hoskin P, West C, Kelly J. Loss of expression of the tumour suppressor gene AIMP3 predicts survival following radiotherapy in muscle‐invasive bladder cancer. International Journal Of Cancer 2014, 136: 709-720. PMID: 24917520, DOI: 10.1002/ijc.29022.Peer-Reviewed Original ResearchConceptsMuscle-invasive bladder cancerMuscle-invasive bladder cancer patientsTissue-microarrayBladder cancerAssociated with survivalPredictive of survivalMethylation-specific PCRColony forming assayLoss of expressionRadical cystectomyRadiotherapy trialsRadiosensitising effectPrognostic valueMechanism of gene silencingRadiotherapyResponse to ionising radiationClinical biomarkersPatientsProtein expressionCancerMeta-analysisDNA damage responseCystectomySurvivalBladder